Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2005 Dec;97(12):1600–1607.

Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.

David T Nash 1
PMCID: PMC2640717  PMID: 16396052

Abstract

Atherosclerosis and the metabolic derangements of insulin resistance, metabolic syndrome and diabetes mellitus are all associated with underlying inflammatory processes. C-reactive protein (CRP), a marker of inflammation, has been shown to be a strong independent predictor of vascular events. It adds to cardiovascular disease risk at all levels of low-density-lipoprotein cholesterol and Framingham risk scores, and elevated levels are also associated with increasing severity of the metabolic syndrome. The development of a simple, stable, noninvasive test to measure high-sensitivity CRP has provided a clinical tool that may have an important role in the identification and assessment of individuals likely to develop cardiovascular or metabolic disease. The role of CRP in predicting cardiovascular risk is less clear in African Americans, however, than in white populations. Statins and thiazolidinediones are being investigated for their potential role in the prevention and treatment of the inflammatory processes involved in the metabolic syndrome and cardiovascular disease. In the future, assessment of CRP levels may contribute importantly to clinical decision-making in reducing cardiovascular risk.

Full text

PDF
1600

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. A., Danielson E., Rifai N., Ridker P. M., PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001 Jul 4;286(1):64–70. doi: 10.1001/jama.286.1.64. [DOI] [PubMed] [Google Scholar]
  2. Albert Michelle A., Glynn Robert J., Buring Julie, Ridker Paul M. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004 May 15;93(10):1238–1242. doi: 10.1016/j.amjcard.2004.01.067. [DOI] [PubMed] [Google Scholar]
  3. Brancati F. L., Kao W. H., Folsom A. R., Watson R. L., Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000 May 3;283(17):2253–2259. doi: 10.1001/jama.283.17.2253. [DOI] [PubMed] [Google Scholar]
  4. Brandon L. Jerome, Mullis Rebecca M., Jonnalagadda Satya S., Hughes Marilyn H. Relationships and CHD risks of BMI, lipoproteins, lipids, and blood pressure in African-American men and women. Prev Med. 2005 Mar;40(3):349–354. doi: 10.1016/j.ypmed.2004.06.013. [DOI] [PubMed] [Google Scholar]
  5. Calabró Paolo, Willerson James T., Yeh Edward T. H. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003 Oct 6;108(16):1930–1932. doi: 10.1161/01.CIR.0000096055.62724.C5. [DOI] [PubMed] [Google Scholar]
  6. Curtis A. B., Strogatz D. S., James S. A., Raghunathan T. E. The contribution of baseline weight and weight gain to blood pressure change in African Americans: the Pitt County Study. Ann Epidemiol. 1998 Nov;8(8):497–503. doi: 10.1016/s1047-2797(98)00024-6. [DOI] [PubMed] [Google Scholar]
  7. Deedwania Prakash C., Hunninghake Donald B., Bays Harold E., Jones Peter H., Cain Valerie A., Blasetto James W., STELLAR Study Group Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005 Feb 1;95(3):360–366. doi: 10.1016/j.amjcard.2004.09.034. [DOI] [PubMed] [Google Scholar]
  8. Duncan Bruce B., Schmidt Maria Inês, Pankow James S., Ballantyne Christie M., Couper David, Vigo Alvaro, Hoogeveen Ron, Folsom Aaron R., Heiss Gerardo, Atherosclerosis Risk in Communities Study Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003 Jul;52(7):1799–1805. doi: 10.2337/diabetes.52.7.1799. [DOI] [PubMed] [Google Scholar]
  9. Festa A., D'Agostino R., Jr, Howard G., Mykkänen L., Tracy R. P., Haffner S. M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 Jul 4;102(1):42–47. doi: 10.1161/01.cir.102.1.42. [DOI] [PubMed] [Google Scholar]
  10. Ford Earl S., Giles Wayne H., Dietz William H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356–359. doi: 10.1001/jama.287.3.356. [DOI] [PubMed] [Google Scholar]
  11. Freeman Dilys J., Norrie John, Caslake Muriel J., Gaw Allan, Ford Ian, Lowe Gordon D. O., O'Reilly Denis St J., Packard Chris J., Sattar Naveed, West of Scotland Coronary Prevention Study C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002 May;51(5):1596–1600. doi: 10.2337/diabetes.51.5.1596. [DOI] [PubMed] [Google Scholar]
  12. Girman Cynthia J., Rhodes Thomas, Mercuri Michele, Pyörälä Kalevi, Kjekshus John, Pedersen Terje R., Beere Polly A., Gotto Antonio M., Clearfield Michael, 4S Group and the AFCAPS/TexCAPS Research Group The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004 Jan 15;93(2):136–141. doi: 10.1016/j.amjcard.2003.09.028. [DOI] [PubMed] [Google Scholar]
  13. Grundy Scott M., Brewer H. Bryan, Jr, Cleeman James I., Smith Sidney C., Jr, Lenfant Claude, American Heart Association. National Heart, Lung, and Blood Institute Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 Jan 27;109(3):433–438. doi: 10.1161/01.CIR.0000111245.75752.C6. [DOI] [PubMed] [Google Scholar]
  14. Haffner Steven M., Greenberg Andrew S., Weston Wayde M., Chen Hongzi, Williams Ken, Freed Martin I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002 Aug 6;106(6):679–684. doi: 10.1161/01.cir.0000025403.20953.23. [DOI] [PubMed] [Google Scholar]
  15. Hanley Anthony J. G., Festa Andreas, D'Agostino Ralph B., Jr, Wagenknecht Lynne E., Savage Peter J., Tracy Russell P., Saad Mohammed F., Haffner Steven M. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004 Jul;53(7):1773–1781. doi: 10.2337/diabetes.53.7.1773. [DOI] [PubMed] [Google Scholar]
  16. Malik Shaista, Wong Nathan D., Franklin Stanley S., Kamath Tripthi V., L'Italien Gilbert J., Pio Jose R., Williams G. Rhys. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004 Aug 23;110(10):1245–1250. doi: 10.1161/01.CIR.0000140677.20606.0E. [DOI] [PubMed] [Google Scholar]
  17. Mokdad A. H., Bowman B. A., Ford E. S., Vinicor F., Marks J. S., Koplan J. P. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001 Sep 12;286(10):1195–1200. doi: 10.1001/jama.286.10.1195. [DOI] [PubMed] [Google Scholar]
  18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143–3421. [PubMed] [Google Scholar]
  19. Nissen Steven E., Tuzcu E. Murat, Schoenhagen Paul, Crowe Tim, Sasiela William J., Tsai John, Orazem John, Magorien Raymond D., O'Shaughnessy Charles, Ganz Peter. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005 Jan 6;352(1):29–38. doi: 10.1056/NEJMoa042000. [DOI] [PubMed] [Google Scholar]
  20. Osei Kwame, Gaillard Trudy, Kaplow June, Bullock Matthew, Schuster Dara. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism. 2004 Dec;53(12):1552–1557. doi: 10.1016/j.metabol.2004.06.023. [DOI] [PubMed] [Google Scholar]
  21. Pasceri V., Willerson J. T., Yeh E. T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 Oct 31;102(18):2165–2168. doi: 10.1161/01.cir.102.18.2165. [DOI] [PubMed] [Google Scholar]
  22. Pearson Thomas A., Mensah George A., Alexander R. Wayne, Anderson Jeffrey L., Cannon Richard O., 3rd, Criqui Michael, Fadl Yazid Y., Fortmann Stephen P., Hong Yuling, Myers Gary L. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499–511. doi: 10.1161/01.cir.0000052939.59093.45. [DOI] [PubMed] [Google Scholar]
  23. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327–334. doi: 10.1001/jama.286.3.327. [DOI] [PubMed] [Google Scholar]
  24. Reaven G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595–1607. doi: 10.2337/diab.37.12.1595. [DOI] [PubMed] [Google Scholar]
  25. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973–979. doi: 10.1056/NEJM199704033361401. [DOI] [PubMed] [Google Scholar]
  26. Ridker P. M., Rifai N., Clearfield M., Downs J. R., Weis S. E., Miles J. S., Gotto A. M., Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001 Jun 28;344(26):1959–1965. doi: 10.1056/NEJM200106283442601. [DOI] [PubMed] [Google Scholar]
  27. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F. M., Moye L. A., Goldman S., Flaker G. C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 Sep 1;98(9):839–844. doi: 10.1161/01.cir.98.9.839. [DOI] [PubMed] [Google Scholar]
  28. Ridker P. M., Rifai N., Pfeffer M. A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 Jul 20;100(3):230–235. doi: 10.1161/01.cir.100.3.230. [DOI] [PubMed] [Google Scholar]
  29. Ridker Paul M., Buring Julie E., Cook Nancy R., Rifai Nader. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 Jan 28;107(3):391–397. doi: 10.1161/01.cir.0000055014.62083.05. [DOI] [PubMed] [Google Scholar]
  30. Ridker Paul M., Cannon Christopher P., Morrow David, Rifai Nader, Rose Lynda M., McCabe Carolyn H., Pfeffer Marc A., Braunwald Eugene, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20–28. doi: 10.1056/NEJMoa042378. [DOI] [PubMed] [Google Scholar]
  31. Ridker Paul M., Cook Nancy. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004 Mar 29;109(16):1955–1959. doi: 10.1161/01.CIR.0000125690.80303.A8. [DOI] [PubMed] [Google Scholar]
  32. Ridker Paul M., JUPITER Study Group Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003 Nov 11;108(19):2292–2297. doi: 10.1161/01.CIR.0000100688.17280.E6. [DOI] [PubMed] [Google Scholar]
  33. Ridker Paul M., Rifai Nader, Rose Lynda, Buring Julie E., Cook Nancy R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557–1565. doi: 10.1056/NEJMoa021993. [DOI] [PubMed] [Google Scholar]
  34. Ridker Paul M., Wilson Peter W. F., Grundy Scott M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004 Jun 15;109(23):2818–2825. doi: 10.1161/01.CIR.0000132467.45278.59. [DOI] [PubMed] [Google Scholar]
  35. Rutter Martin K., Meigs James B., Sullivan Lisa M., D'Agostino Ralph B., Sr, Wilson Peter W. F. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004 Jul 19;110(4):380–385. doi: 10.1161/01.CIR.0000136581.59584.0E. [DOI] [PubMed] [Google Scholar]
  36. Sidhu Jagdip S., Cowan Dahlia, Kaski Juan-Carlos. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003 Nov 19;42(10):1757–1763. doi: 10.1016/j.jacc.2003.04.001. [DOI] [PubMed] [Google Scholar]
  37. Thorand Barbara, Löwel Hannelore, Schneider Andrea, Kolb Hubert, Meisinger Christa, Fröhlich Margit, Koenig Wolfgang. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003 Jan 13;163(1):93–99. doi: 10.1001/archinte.163.1.93. [DOI] [PubMed] [Google Scholar]
  38. Tillett W. S., Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med. 1930 Sep 30;52(4):561–571. doi: 10.1084/jem.52.4.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Venugopal Senthil Kumar, Devaraj Sridevi, Yuhanna Ivan, Shaul Philip, Jialal Ishwarlal. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002 Sep 17;106(12):1439–1441. doi: 10.1161/01.cir.0000033116.22237.f9. [DOI] [PubMed] [Google Scholar]
  40. Verma Subodh, Wang Chao-Hung, Li Shu-Hong, Dumont Aaron S., Fedak Paul W. M., Badiwala Mitesh V., Dhillon Bikramjit, Weisel Richard D., Li Ren-Ke, Mickle Donald A. G. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002 Aug 20;106(8):913–919. doi: 10.1161/01.cir.0000029802.88087.5e. [DOI] [PubMed] [Google Scholar]
  41. Williams Takeyla N., Zhang Cecelia X., Game Bryan A., He Lin, Huang Yan. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2003 Oct 30;24(1):61–66. doi: 10.1161/01.ATV.0000104014.24367.16. [DOI] [PubMed] [Google Scholar]
  42. Yeh Edward T. H., Willerson James T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003 Jan 28;107(3):370–371. doi: 10.1161/01.cir.0000053731.05365.5a. [DOI] [PubMed] [Google Scholar]
  43. Yudkin J. S., Stehouwer C. D., Emeis J. J., Coppack S. W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972–978. doi: 10.1161/01.atv.19.4.972. [DOI] [PubMed] [Google Scholar]
  44. Zwaka T. P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001 Mar 6;103(9):1194–1197. doi: 10.1161/01.cir.103.9.1194. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES